HOME >> BIOLOGY >> NEWS
Drug breaks for HIV-infected individuals may put certain immune cells at risk

DALLAS May 2, 2002 Disruption of antiretroviral therapy by patients infected with HIV may be putting certain T-cells in their bloodstream at greater risk for infection with the deadly virus if it is allowed to rebound, a study in the May 2 issue of the journal Nature concludes.

Patients whose viral counts have fallen to nearly imperceptible levels sometimes interrupt antiviral therapy temporarily, re-starting treatment if viral levels rebound. Called structured therapy interruption, these drug breaks can increase the number of certain HIV-fighting T-cells, called CD8 T-cells, in the blood. Another type of T-cell, CD4, also plays an important role in fighting HIV.

Using data collected at UT Southwestern Medical Center at Dallas, researchers have found that, even though CD8 cells increase in number with interruption of therapy, HIV-specific CD4 cells appear to be particularly prone to infection by the virus during treatment interruption. Infections of CD4 cells hasten their destruction and help spread the disease to other cells in the body.

In time, as the patients immune system is progressively weakened, this can give rise to full-blown AIDS, researchers say.

The patient can begin taking antiviral drugs to control the virus again, although this therapy is not a cure. It is unknown how long it takes for the body to regenerate these HIV-specific CD4 cells once the bodys supply has become infected, or even if regeneration occurs with re-initiation of anti-viral treatment.

During the treatment interruption, although HIV-fighting CD8 cells increase, HIV-specific CD4 cells also become infected if the virus is allowed to rebound, said Dr. Joseph Casazza, a co-author and assistant professor of infectious disease at UT Southwestern. In effect, by taking a drug break, you could be robbing Peter to pay Paul.


'"/>

Contact: Mindy Baxter
melinda.baxter@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
1-May-2002


Page: 1

Related biology news :

1. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
2. New model explains why costly insect outbreaks hard to predict
3. Spruce bark beetle outbreaks examined at Alaska Symposium
4. Ebola outbreaks are simultaneous mini-epidemics
5. Mustard-root map breaks new ground tracking gene expression
6. $51 million research facility, classroom complex breaks ground at UH
7. Some 400 fragile regions of genome more vulnerable to evolutionary breaks
8. System failure to blame for Walkerton, North Battleford outbreaks, says U of T study
9. As Vitamin B-6 levels go down, numbers of DNA strand breaks go up
10. Checkpoint protein blocks chromosome breaks at fragile sites
11. Insect infestation models may shed light on insect and disease outbreaks

Post Your Comments:
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
(Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
(Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
(Date:3/25/2015)... CA (PRWEB) March 25, 2015 ... for Novel Mechanism of Action in Neuromuscular Diseases ... 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the ... skeletal muscle troponin activator tirasemtiv in the journal ... Phase IIa “Evidence of Effect” or hypothesis-generating clinical ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: